» Articles » PMID: 35464057

Endothelial Dysfunction and Diabetic Cardiomyopathy

Overview
Specialty Endocrinology
Date 2022 Apr 25
PMID 35464057
Authors
Affiliations
Soon will be listed here.
Abstract

The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.

Citing Articles

Endothelial Markers in Type 2 Diabetic Patients with Acute Decompensated Heart Failure: A Pilot Study.

Pec M, Jurica J, Bolek T, Skornova I, Pecova M, Cingel M Metabolites. 2025; 15(2).

PMID: 39997716 PMC: 11857251. DOI: 10.3390/metabo15020091.


The application of procyanidins in diabetes and its complications: a review of preclinical studies.

Zhang Y, Li M, Liu H, Fan Y, Liu H Front Pharmacol. 2025; 16:1532246.

PMID: 39995417 PMC: 11847907. DOI: 10.3389/fphar.2025.1532246.


L-arginine administration exacerbates myocardial injury in diabetics prooxidant and proinflammatory mechanisms along with myocardial structural disruption.

Mansouri R, Aboubakr E, Alshaibi H, Ahmed A World J Diabetes. 2025; 16(2):100395.

PMID: 39959273 PMC: 11718468. DOI: 10.4239/wjd.v16.i2.100395.


Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure.

Zhang Y, Liu Y, Yang W World J Cardiol. 2025; 17(1):100886.

PMID: 39866214 PMC: 11755127. DOI: 10.4330/wjc.v17.i1.100886.


Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.

Khattab E, Kyriakou M, Leonidou E, Sokratous S, Mouzarou A, Myrianthefs M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861195 PMC: 11768626. DOI: 10.3390/ph18010134.


References
1.
Picano E . Diabetic cardiomyopathy. the importance of being earliest. J Am Coll Cardiol. 2003; 42(3):454-7. DOI: 10.1016/s0735-1097(03)00647-8. View

2.
Saraiva R, Minhas K, Zheng M, Pitz E, Treuer A, Gonzalez D . Reduced neuronal nitric oxide synthase expression contributes to cardiac oxidative stress and nitroso-redox imbalance in ob/ob mice. Nitric Oxide. 2007; 16(3):331-8. PMC: 2754218. DOI: 10.1016/j.niox.2006.12.001. View

3.
Zhou H, Zhang R, Anand P, Stomberski C, Qian Z, Hausladen A . Metabolic reprogramming by the S-nitroso-CoA reductase system protects against kidney injury. Nature. 2018; 565(7737):96-100. PMC: 6318002. DOI: 10.1038/s41586-018-0749-z. View

4.
Abbasi F, Asagmi T, Cooke J, Lamendola C, McLaughlin T, Reaven G . Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001; 88(10):1201-3. DOI: 10.1016/s0002-9149(01)02063-x. View

5.
Liefeldt L, Rylski B, Walcher F, Manhart J, Kron S, Rosenke Y . Effects of transgenic endothelin-2 overexpression on diabetic cardiomyopathy in rats. Eur J Clin Invest. 2010; 40(3):203-10. DOI: 10.1111/j.1365-2362.2009.02251.x. View